Your blog category
Neu-001, a first-in-class neural plasticity modulator designed to restore visual function in patients with amblyopia, has officially entered Phase 2a clinical development. This multicenter clinical study is designed primarily to evaluate safety, tolerability, and dose response across multiple dosing regimens…
On April 29, 2026, the 16th Accelerator Pitch Day, hosted by Moordn Institute in collaboration with leading partner institutions, was successfully held in Guangzhou. The event brought together more than 50 representatives from investment and financial institutions, alongside over 100…
NeuDirection announces that its innovative drug Neu-001 for the treatment of amblyopia has successfully completed its Phase I clinical trial. The trial results demonstrated favorable safety and tolerability profiles, establishing a solid foundation for further clinical development. Neu-001 is a…